Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Core Viewpoint - Genelux Corporation is advancing its Olvi-Vec program in multiple solid tumor indications, with significant clinical milestones expected in the coming year, particularly in ovarian and lung cancer, which represent a multi-billion-dollar market opportunity [2][3][5] Clinical Program Highlights - Olvi-Vec is being developed for platinum-resistant/refractory ovarian cancer, with intraperitoneal administration aimed at delivering high doses to patients needing effective anti-tumor options [3][5] - Two ongoing trials for lung cancer are assessing the systemic delivery of Olvi-Vec, with the goal of demonstrating its efficacy across various solid tumors and its potential to resensitize tumors to platinum-based chemotherapy [3][6] - The Phase 3 OnPrime trial for ovarian cancer is expected to provide topline data in the second half of 2026, with the Independent Data Monitoring Committee recommending the continuation of the trial without modifications [5][6] Financial Results - As of September 30, 2025, the company reported cash, cash equivalents, short-term investments, and restricted cash totaling $21.0 million, which is expected to fund operations into the third quarter of 2026 [4][7] - Research and development expenses increased to $4.7 million in Q3 2025 from $4.1 million in Q3 2024, primarily due to stock compensation and increased clinical trial costs [8] - General and administrative expenses rose to $3.5 million in Q3 2025 from $2.9 million in Q3 2024, driven by stock compensation and salary increases [9] - The net loss for Q3 2025 was $8.0 million, or $0.21 per share, compared to a net loss of $6.5 million, or $0.19 per share, in Q3 2024 [9][15]